Find Clinical Drug Pipeline Developments & Deals for Galidesivir

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galidesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: BCX4430

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institute of Health

            Deal Size: $44.0 million Upfront Cash: Undisclosed

            Deal Type: Funding August 31, 2020

            Details:

            The additional funds under these performance-based contracts support, The completion of parts 1 and 2 of an ongoing clinical trial of galidesivir in Brazil.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galidesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            Details:

            Galidesivir is an investigational broad-spectrum antiviral drug that was safe and well tolerated in previously reported Phase 1 trials in healthy subjects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galidesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 02, 2020

            Details:

            Galidesivir has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses and coronaviruses.